A GLP-1 receptor agonist is a medication that reproduces the effects of the GLP-1 hormone. This guide explains what the class is, how it works, which compounds are FDA-approved as of April 2026, and the genetic variables that sit upstream of every GLP-1 decision.

This overview focuses on the injectable form of semaglutide for weight management, from its GLP-1 mechanism and the SUSTAIN, STEP, and PIONEER evidence to approvals, contraindications, and the inherited variants that shape metabolism. Every figure stays anchored to published labeling and literature.

GLP-1 receptor agonists have reshaped the way people talk about weight management. This overview explains the mechanism in plain terms, walks through the major trial programs and their reported effect sizes, traces the approval timeline, flags the key limitations, and shows how inherited traits shape the metabolic picture.

Rybelsus (oral semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Zepbound and Mounjaro are the same tirzepatide molecule from Eli Lilly, separated only by the FDA indication each brand carries. This editorial comparison, current as of April 2026, explains the labeling split, the SURMOUNT and SURPASS evidence, list prices, and the shared genetics.

Mounjaro and Zepbound share a single tirzepatide molecule sold under two Eli Lilly labels. This independent comparison explains why one manufacturer uses two brand names, how their FDA indications and trials diverge, how they are priced as of April 2026, and why the underlying genetics stay identical either way.

Zepbound and Ozempic are different molecules with different receptor strategies: tirzepatide adds a GIP arm that semaglutide lacks. This editorial comparison, current as of April 2026, weighs their approved uses, SURMOUNT and SUSTAIN evidence, list prices, and shared genetic terrain.

Semaglutide tablets are the oral route into the GLP-1 pathway. This page covers what oral options are FDA-approved, how a peptide survives digestion through an absorption enhancer, how tablets compare with weekly injection, what they cost, and the genetic context underneath.

Ozempic and Mounjaro sit at different points on the incretin spectrum: one is a GLP-1-selective agonist, the other a dual GIP and GLP-1 agonist. This independent review compares their molecular design, FDA labels, trial programs, safety, monthly cost, and the shared genetics that sit beneath both compounds.

This independent comparison of Mounjaro and Ozempic covers how each engages the incretin system, where their FDA labels diverge, what the SURPASS and SUSTAIN trial programs measured, published list pricing as of April 2026, and the shared genetic pathways that sit above both molecules regardless of which is prescribed.

Zepbound and Wegovy were both brought to market specifically for chronic weight management, making this a direct obesity-treatment comparison. As of April 2026, this editorial piece contrasts their dual-versus-selective design, STEP and SURMOUNT evidence, list prices, and shared genetic terrain.

Wegovy and Zepbound are the two injectables FDA-approved specifically for chronic weight management, making this a rare like-for-like comparison. This independent review sets single-hormone semaglutide against dual-hormone tirzepatide on action, labels, evidence, safety, and cost, then the genetics both share as a common starting line.

Here is the catch most Wegovy-versus-Ozempic searches miss: both are the same molecule, semaglutide, sold under two brand names. This independent review explains where dose, indication, price, and coverage actually diverge, and why the underlying genetics stay identical no matter which label you fill.

The GLP-1 medication category has grown quickly and can be hard to keep straight. This roster explains what the hormone is, how the receptor-agonist class works, which compounds are FDA-approved as of April 2026, and the inherited variables that sit beneath the pathway.

Ozempic and Wegovy share one molecule, semaglutide, but carry different FDA indications and doses. This independent review explains why the underlying pharmacology stays identical while the labels, trial programs, list price, and appetite genetics that shape each decision are what actually set them apart.

Interest in a semaglutide pill keeps growing. This guide explains which oral GLP-1 options are FDA-approved, how absorption technology makes a pill possible, how oral and injectable delivery differ, what drives cost, and the genetic context behind any semaglutide decision.

Microdose GLP-1 protocols use lower-than-standard doses of GLP-1 receptor agonists titrated by a clinician for better tolerability. This article covers what microdose means, the rationale, and the PlexusDx Microdose GLP-1 protocol inside the Weight Management Protocols collection.

Ozempic Vulva explained — what is being described, why it can happen, what the published trial evidence shows, and the GLP-1 pathway genetic context. Treated with clinical dignity. Individual results vary.

GLP-1 drugs are engineered from a natural gut hormone that resists rapid breakdown. This article traces the biology, explains how the receptor agonist class works, lists the FDA-approved and investigational compounds as of April 2026, and covers the genetics sitting upstream.

GLP-1 was a gut hormone long before it was a medication. This PlexusDx explainer defines glucagon-like peptide-1, follows its actions, explains why it was engineered into a drug class, lists the approved compounds, and turns to the GLP1R pathway underneath.

Searching for GLP-1 pills usually means wanting appetite and glucose support without a weekly shot. This guide covers the single FDA-approved oral option, why swallowing a peptide is difficult, the compounded and investigational landscape, and how the format you choose shapes both the routine and the cost.

Searching for a Wegovy pill leads somewhere unexpected: the injection has no tablet form. This guide explains the oral GLP-1 products that genuinely exist, why swallowing a peptide is difficult, how a pill compares with the weekly shot, and where your genetics fit.

Ozempic (semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Wegovy (semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Can you take a GLP-1 as a pill? This article covers what is approved in tablet form, why turning a peptide into an oral medicine is difficult, how a pill compares to a weekly injection, what an oral option costs, and the genetic context that applies under any format.

There is no Wegovy pill — Wegovy is injection-only. This page explains which oral GLP-1 options exist in April 2026, how an oral peptide manages to survive the stomach, how the pills compare with the weekly injection, and what the oral options actually cost.

Ozempic Face explained — what is being described, why it can happen, what the published trial evidence shows, and the GLP-1 pathway genetic context. Treated with clinical dignity. Individual results vary.

Peptide protocols fail many people not because the science is wrong, but because they're built for population averages. FTO, FOXO3, ACTN3, SHBG, and COMT variants mean weight management, longevity, muscle, and hormone biology works differently in everyone. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights to reveal exactly where your biology diverges.

The Precision Peptide Genetic Test analyzes how your genes relate to the pathways targeted by 49 unique compounds across 14 areas of health, from weight management and GLP-1 biology to muscle growth, longevity, and sleep. This post breaks down what the 49-peptide panel covers and how each pathway maps to your genetics.

Your Precision Peptide Genetic Test report delivers 150+ insights across 14 pathways, including FOXO3 for longevity, ACTN3 for muscle, and GIPR for weight management. This guide walks through how to read pathway scores, interpret gene variants, and turn findings into the informed conversation every peptide protocol decision should start with.